- ►duanessolution.com FR Imrie, AD Dick - Current Opinion in Ophthalmology, 2007 - journals.lww.com Recent findings: The anti-tumour necrosis factor-α infliximab and adalimumab
have demonstrated significant efficacy in controlling uveitis associated with
seronegative spondyloarthropathies and juvenile idiopathic arthritis; ... Cited by 19 - Related articles - BL Direct - All 4 versions
J Plskova, K Greiner, JV Forrester - American Journal of Ophthalmology, 2007 - Elsevier The mean observation period was 11 months (range, one to 29 months). A positive
clinical response was observed in 83% of patients. Median visual acuity improved
from 0.54 to 0.2 (logarithm of the minimum angle of resolution units; P < ... Cited by 15 - Related articles - All 12 versions
RW Read - Current rheumatology reports, 2006 - Springer Uveitis is a leading cause of blindness affecting indi- viduals of all ages,
genders, and races. Uveitis may be due to autoimmune, infectious, toxic,
malignant, or traumatic processes. Some evidence supports an asso- ciation ... Cited by 14 - Related articles - BL Direct - All 4 versions
MT Lee, LC Hooper, L Kump, K Hayashi, R … - Clinical and Experimental Immunology, 2007 - pubmedcentral.nih.gov Retinal vasculitis is a major component of ocular inflammation that plays a role
in retinal tissue damage in patients with idiopathic uveitis and Behçet's
disease. Here we show that type 1 interferons (IFN α/β) were not detected ... Cited by 10 - Related articles - BL Direct - All 6 versions
FR Imrie, AD Dick - Current Opinion in Ophthalmology, 2007 - journals.lww.com Purpose of review This review summarizes current nonsteroidal drug therapies for
noninfectious posterior and intermediate uveitis. Recent findings Continuing
evidence shows that second-line agents including antimetabolites, T-cell ... Cited by 9 - Related articles - BL Direct - All 2 versions
- ►prsjournal.com A Rothova - Current Opinion in Ophthalmology, 2007 - journals.lww.com Purpose of review The aim of this article is to update our current understanding
and management of inflammatory cystoid macular edema. Recent findings Cystoid
macular edema is a common cause of visual loss in uveitis, which occurs ... Cited by 9 - Related articles - BL Direct - All 6 versions
F Mackensen, R Max, MD Becker - Current opinion in ophthalmology, 2006 - journals.lww.com The authors performed an investigator-initiated, randomized, controlled clinical
trial on interferon-β in the treatment of intermediate uveitis. Expenses were
partially covered by a donation from Serono GmbH. The authors have no ... Cited by 7 - Related articles - BL Direct - All 3 versions
SM Maca, M Scharitzer, T Barisani-Asenbauer - Wiener Klinische Wochenschrift, 2006 - Springer Page 1. 273 Maca et al., Uveitis and neurologic diseases: an often overlooked
relationship Wien Klin Wochenschr (2006) 118/9–10 ... Cited by 4 - Related articles - BL Direct - All 3 versions
JA Montero, ME Sanchis, M Fernandez- … - Journal of Neuro-Ophthalmology, 2007 - journals.lww.com Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the
central nervous system predominantly affecting young adults. The eyes may have
retrobulbar optic neuritis (ON) and papillitis ( 1-4 ), intermediate ... Cited by 2 - Related articles - BL Direct - All 3 versions
S Fraser-Bell, C Pavesio - Expert Review of Ophthalmology, 2008 - ingentaconnect.com Owing to the propensity for visual loss, immunosuppressive treatment in the form
of systemic and/or local therapy is often required for the management of
noninfective intermediate and posterior uveitis. Systemic corticosteroids ... Cited by 1 - Related articles - All 8 versions
